Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC).

PHASE2UnknownINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

October 7, 2019

Primary Completion Date

March 31, 2022

Study Completion Date

June 30, 2022

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Anlotinib Hydrochloride, Paclitaxel, cisplatin

"* anlotinib: 1 capsule (10mg) once a day, d1-d14 per cycle, 3 weeks for a treatment cycle.~* Paclitaxel: intravenously infused at 135mg/ m2, administered d1 per cycle, 3 weeks for a treatment cycle.~* Cisplatin: administered after paclitaxel, intravenously infused at 60-75 mg/m2, divided into d1-d3 medications per cycle; 3 weeks for one treatment cycle."

Trial Locations (6)

450000

Henan cancer hospital, Zhengzhou

455000

ANYANG Cancer Hospital, Anyang

Unknown

First Affiliated Hospital of Henan University of Science and Technolog, Luoyan

Qilu Hospital, Jinan

Shandong Cancer Hospital, Jinan

Linyi Central Hospital, Linyi

All Listed Sponsors
collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

Henan Cancer Hospital

OTHER_GOV